Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Pre-existing retinal inflammation exacerbates gene therapy-associated uveitis in more rapidly progressive retinal degeneration.

Molecular therapy. Advances·2026
Same author

Subretinal injection in the USH1CR31∗ pig model leads to chorioretinal atrophy that limits evaluation of efficacy of an AAV-mediated gene therapy.

Experimental eye research·2026
Same author

Microperimetry as an Outcome Measure Improves Patient Eligibility and Efficacy Detection in RPGR Gene Therapy Trials.

American journal of ophthalmology·2026
Same author

Gene therapy development for retinal diseases.

Handbook of clinical neurology·2026
Same author

Centripetal Retinal Degeneration Follows an Exponential Decay and May Be Reversed Following Gene Therapy.

American journal of ophthalmology·2026
Same author

Exploring fundus-controlled mesopic and scotopic perimetry in inherited retinal disease.

Acta ophthalmologica·2026

相关实验视频

Updated: Jul 15, 2025

Enrichment of Bruch's Membrane from Human Donor Eyes
10:22

Enrichment of Bruch's Membrane from Human Donor Eyes

Published on: November 15, 2015

12.1K

冠状腺症:终点终点游戏的终点

Maram E A Abdalla Elsayed1,2, Laura J Taylor1,2, Amandeep S Josan1,2

  • 1Oxford Eye Hospital, Oxford University Hospitals National Health Service Foundation Trust, Oxford OX3 9DU, UK.

International journal of molecular sciences
|September 28, 2023
PubMed
概括

胆血症是一种X相关的视网膜疾病,导致逐渐视力丧失. 基因疗法对治疗有希望,本次审查分析了临床试验数据,以指导对这种遗传性视网膜退行症的未来策略.

关键词:
在 AAV AAV AAV 中.在CHM基因基因中.在 REP1 中, REP1 是 REP1 的代名词.反感的寡核化物.胆固醇血症是一种疾病.临床试验是指临床试验中的临床试验.终点 终点 终点 终点基因治疗的基因疗法没有意义的抑制疗法.结果措施的结果措施.

更多相关视频

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.1K
Assessment and Characterization of Hyaloid Vessels in Mice
08:22

Assessment and Characterization of Hyaloid Vessels in Mice

Published on: May 15, 2019

9.2K

相关实验视频

Last Updated: Jul 15, 2025

Enrichment of Bruch's Membrane from Human Donor Eyes
10:22

Enrichment of Bruch's Membrane from Human Donor Eyes

Published on: November 15, 2015

12.1K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.1K
Assessment and Characterization of Hyaloid Vessels in Mice
08:22

Assessment and Characterization of Hyaloid Vessels in Mice

Published on: May 15, 2019

9.2K

科学领域:

  • 眼科医生 眼科 眼科
  • 遗传学 遗传学是一种遗传学.
  • 视网膜退化 视网膜退化

背景情况:

  • 胆血症是一种X链接的遗传性视网膜变性.
  • 由于视网膜色素表皮的退化,它导致光受体和胆囊细胞的逐渐丧失.
  • 症状包括夜盲和外周视力丧失,进展到中心视力受损.

研究的目的:

  • 审查从胆固醇病临床试验中学到的经验教训.
  • 分析当前用于胆固醇病研究的终点.
  • 为有效的临床试验提出未来的战略.

主要方法:

  • 出版的临床试验的文献综述在胆固醇血症.
  • 对基因疗法研究中的结果测量和终点的分析.
  • 综合发现,以告知未来的试验设计.

主要成果:

  • 临床试验为管理胆血症提供了宝贵的见解.
  • 标准化终点对于评估治疗疗效至关重要.
  • 基因疗法是阻止疾病进展的有希望的方法.

结论:

  • 临床试验设计的进一步细化对于胆固醇血症是必要的.
  • 优化的终点将加速有效疗法的开发.
  • 基因疗法具有治疗这种疾病的巨大潜力.